CurrentCignaPolicy 0195

Gynecomastia surgical management (Coverage Policy)

This policy governs medical coverage for surgical correction of gynecomastia and related clinical considerations for Cigna members. It affects providers submitting claims or requesting prior authorization for gynecomastia procedures.

Policy Summary

PayerCigna

PolicyGynecomastia surgical management (Coverage Policy)

Policy CodePolicy 0195

Change TypeAnnual review — no clinical policy statement changes

Effective Date

Next Review DateAug 15, 2025

Key ActionProvide documentation and clinical references to support medical necessity when requesting coverage for gynecomastia surgery.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Annual reviewpolicy reviewed yearly

No changesrecent annual reviews

9-28 refsliterature citations in this part

Provider Actions and Authorization Notes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Documentation Required

Documentation — Clinical References

Extensive clinical references are available to support documentation and clinical justification for treatment decisions (peer-reviewed literature, clinical society guidance, and UpToDate). Providers should cite pertinent references in submitted documentation when relevant.

Representative citations available in policy references (see Reference list)
Include pertinent peer-reviewed citations with clinical documentation when applicable

Background and Clinical Evidence

This policy references a broad literature base that supports the clinical evaluation and operative management of gynecomastia, including guideline-like resources and multiple surgical series. Key sources cited include society guidance (American Society of Plastic Surgeons), specialty reviews and systematic reviews, and clinical references such as the Endocrine Society, Mayo Clinic, and UpToDate, which provide context on diagnosis, grading, and nonoperative management.

Surgical technique literature cited in the policy covers a range of approaches used to treat gynecomastia: skin-sparing mastectomy with or without liposuction, mastectomy with skin reduction, subcutaneous mastectomy and reduction mammoplasty, as well as adjunctive methods such as suction-assisted and ultrasound-assisted liposuction and combined pull-through techniques. Systematic reviews and comparative series note that combined excision plus aspiration techniques may reduce complication rates compared with excision alone, but also emphasize heterogeneity in surgical classification and technique across studies.

Complication data from the cited reviews include reported ranges for major complications (0% to 33%) and common events such as hematoma (approximately 5.8%) and seroma (approximately 2.4%); use of drains and the distribution of higher-grade gynecomastia cases influences observed complication rates. The literature also highlights that liposuction alone removes adipose but not glandular tissue and therefore is not sufficient as a sole treatment for true gynecomastia.

The references further describe evaluation and management considerations: physical exam and imaging (mammography/ultrasound) to confirm glandular tissue, use of hormone testing to exclude treatable endocrine causes, and the role of medical therapy primarily in the proliferative phase. The policy cites these clinical sources to justify criteria that require documentation of true (glandular) gynecomastia, grading severity, exclusion or treatment of hormonal or drug-induced causes, and persistence of symptoms before surgical intervention.

Finally, the policy underwent routine annual review with no changes to clinical policy statements, and the reference list (including multiple surgical studies and reviews) supports the policy’s assessments of indications, techniques, and complication profiles used to inform coverage guidance.